| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 23072 |
| Drug | Zanubrutinib |
| Brand | Brukinsa® |
| Indication | Zanubrutinib monotherapy is indicated for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy. |
| Assessment Process | |
| Rapid review commissioned | 01/12/2023 |
| Rapid review completed | 09/01/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of zanubrutinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2024 |
